-
Loading metrics
Open Access
Peer-reviewed
Research Article
- Elaine W. Butterly,
- Peter Hanlon,
- Anoop S. V. Shah,
- Laurie J. Hannigan,
- Emma McIntosh,
- Jim Lewsey,
- Sarah H. Wild,
- Bruce Guthrie,
- Frances S. Mair,
- David M. Kent
x
- Published: January 17, 2023
- https://doi.org/10.1371/journal.pmed.1004154
Abstract
Background
Health-related prime of beingness metrics measure treatments successful ways that substance to patients, truthful are often included successful randomised objective trials (hereafter trials). Multimorbidity, wherever individuals person 2 oregon much conditions, is negatively associated with prime of life. However, whether multimorbidity predicts alteration implicit clip oregon modifies attraction effects for prime of beingness is unknown. Therefore, clinicians and line developers are uncertain astir the applicability of proceedings findings to radical with multimorbidity. We examined whether comorbidity number (higher counts indicating greater multimorbidity) (i) is associated with prime of beingness astatine baseline; (ii) predicts alteration successful prime of beingness implicit time; and/or (iii) modifies attraction effects connected prime of life.
Methods and findings
Included trials were registered connected the United States trials registry for selected scale aesculapian conditions and cause classes, signifier 2/3, 3 oregon 4, had ≥300 participants, a nonrestrictive precocious property limit, and were disposable connected 1 of 2 proceedings repositories connected 21 November 2016 and 18 May 2018, respectively. Of 124 gathering these criteria, 56 trials (33,421 participants, 16 scale conditions, and 23 cause classes) collected a generic prime of beingness result measurement (35 EuroQol-5 magnitude (EQ-5D), 31 36-item abbreviated signifier survey (SF-36) with 10 collecting both). Blinding and completeness of travel up were examined for each trial.
Using trials wherever idiosyncratic subordinate information (IPD) was disposable from 2 repositories, a comorbidity number was calculated from aesculapian past and/or prescriptions data. Linear regressions were fitted for the relation betwixt comorbidity number and (i) prime of beingness astatine baseline; (ii) alteration successful prime of beingness during proceedings travel up; and (iii) attraction effects connected prime of life. These results were past combined successful Bayesian linear models. Posterior samples were summarised via the mean, 2.5th and 97.5th percentiles arsenic credible intervals (95% CI) and via the proportionality with values little than 0 arsenic the probability (PBayes) of a antagonistic association.
All results are successful standardised units (obtained by dividing the EQ-5D/SF-36 estimates by published colonisation modular deviations). Per further comorbidity, adjusting for property and sex, crossed each scale conditions and attraction comparisons, comorbidity number was associated with little prime of beingness astatine baseline and with a diminution successful prime of beingness implicit clip (EQ-5D −0.02 [95% CI −0.03 to −0.01], PBayes > 0.999). Associations were similar, but with wider 95% CIs crossing the null for SF-36-PCS and SF-36-MCS (−0.05 [−0.10 to 0.01], PBayes = 0.956 and −0.05 [−0.10 to 0.01], PBayes = 0.966, respectively). Importantly, determination was nary grounds of immoderate enactment betwixt comorbidity number and attraction efficacy for either EQ-5D oregon SF-36 (EQ-5D −0.0035 [95% CI −0.0153 to −0.0065], PBayes = 0.746; SF-36-MCS (−0.0111 [95% CI −0.0647 to 0.0416], PBayes = 0.70 and SF-36-PCS −0.0092 [95% CI −0.0758 to 0.0476], PBayes = 0.631.
Conclusions
Treatment effects connected prime of beingness did not disagree by multimorbidity (measured via a comorbidity count) astatine baseline—for the aesculapian conditions studied, types and severity of comorbidities and level of prime of beingness astatine baseline, suggesting that grounds from objective trials is apt to beryllium applicable to settings with (at slightest modestly) higher levels of comorbidity.
Trial registration
A prespecified protocol was registered connected PROSPERO (CRD42018048202).
Author summary
Why was this survey done?
- ➢ The EuroQol-5 magnitude (EQ-5D) and SF-36 are questionnaire-based tools that harvester measures of physical and intelligence health into wide prime of beingness scores. These scores are utilized successful randomised controlled trials of cause treatments to estimation however treatments impact prime of life. These estimates past pass decisions astir which treatments should beryllium offered to radical with circumstantial conditions.
- ➢ Multimorbidity, the beingness of 2 oregon much conditions, makes diagnosis and attraction much analyzable and is associated with worse prime of beingness successful immoderate settings.
- ➢ People with multimorbidity are underrepresented successful objective trials, and small is known astir whether and however multimorbidity changes prime of beingness successful objective trials. This makes it hard for clinicians and objective line developers to find however results from objective trials should beryllium applied to radical with multimorbidity.
What did the researchers bash and find?
- ➢ To code this uncertainty, we re-analysed information from existing objective trials. Among 33,421 participants successful 56 trials of caller treatments for 16 antithetic aesculapian conditions, we utilized information connected medicine usage and aesculapian histories to nutrient a comorbidity number (higher counts indicating much multimorbidity) for each individual.
- ➢ We past utilized statistical models to analyse associations for comorbidity counts uncovering that higher comorbidity counts were associated with worse prime of beingness astatine proceedings introduction and predicted a much accelerated diminution successful prime of beingness implicit the people of the trial. However, having a higher comorbidity number did not alteration the effect of attraction connected prime of life.
What bash these findings mean?
- ➢ These findings suggest that wherever treatments amended prime of beingness for participants overall, they are likewise apt to bash truthful for radical with multimorbidity.
- ➢ Whether this is existent for individuals with higher numbers of comorbidities oregon with conditions and treatments not included successful our analyses remains uncertain.
- ➢ Nonetheless, our findings assistance pass objective decision-making by reassuring clinicians, wellness economists, and line developers that overall proceedings results tin beryllium utilized erstwhile considering however champion to negociate galore radical with multimorbidity.
Citation: Butterly EW, Hanlon P, Shah ASV, Hannigan LJ, McIntosh E, Lewsey J, et al. (2023) Comorbidity and health-related prime of beingness successful radical with a chronic aesculapian information successful randomised objective trials: An idiosyncratic subordinate information meta-analysis. PLoS Med 20(1): e1004154. https://doi.org/10.1371/journal.pmed.1004154
Received: June 24, 2022; Accepted: December 9, 2022; Published: January 17, 2023
Copyright: © 2023 Butterly et al. This is an unfastened entree nonfiction distributed nether the presumption of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction successful immoderate medium, provided the archetypal writer and root are credited.
Data Availability: The information that enactment the findings of this survey are disposable from Clinical Study Data Request and the Yale Open Data Access repositories but restrictions use to the availability of these data, which were utilized nether licence for the existent study, and truthful are not publically available. Data are nevertheless disposable by straight applying to these repositories via exertion process to their respective autarkic information entree committees. All information released from the respective harmless havens (Clinical Study Data Request and the Yale Open Data Access) has been made disposable astatine https://github.com/ChronicDiseaseEpi/como_qol_public.
Funding: DM is funded via an Intermediate Clinical Fellowship and Beit Fellowship from the Wellcome Trust, who besides supported different costs related to this task specified arsenic information entree costs and database licenses (“Treatment effectiveness successful multimorbidity: Combining efficacy estimates from objective trials with the earthy past obtained from ample regular healthcare databases to find nett wide attraction Benefits.” - 201492/Z/16/Z. SD is supported by the Medical Research Council [grant no. MR/R025223/1]. LH is supported by the South-Eastern Norway Regional Health Authority (#2020023, #2019097). PH is funded done a Clinical Research Training Fellowship from the Medical Research Council (Grant reference: MR/S021949/1). The funders had nary relation successful survey design, information postulation and analysis, determination to publish, oregon mentation of the manuscript.
Competing interests: I person work the journal’s argumentation and the authors of this manuscript person the pursuing competing interests. NJW has received honoraria for grooming and masterclasses from: Association of British Pharmaceutical Industries, Campbell Ireland, Centre for Global Development, NICE International and NICE Scientific Advice, All Wales Therapeutics and Toxicology Centre, University of Leuven. NJW has delivered grooming for Takeda, ICON plc, and University of Galway for which outgo was made to her institution. DM has received backing for this enactment from the Wellcome Trust.
Abbreviations: ATC, anatomic therapeutic chemical; CSDR, Clinical Study Data Request; EQ-5D, EuroQol-5 dimension; IPD, idiosyncratic subordinate data; MCS, intelligence constituent score; NCT, nationalist objective trial; PCS, carnal constituent score; SD, modular deviation; SLE, systemic lupus erythematosus; TNF-α, tumour necrosis origin α; YODA, Yale University Open Data Access
Introduction
Measures of health-related prime of beingness measure the interaction of treatments successful ways that substance to patients [1], and, by informing economical models, are important underpinnings of objective line recommendations and truthful objective practice. Generic prime of beingness measures, specified arsenic the EuroQol-5 magnitude (EQ-5D) [2] and the 36-item abbreviated signifier survey (SF-36) [3] are valid crossed each conditions. This means they tin beryllium utilized to prioritise treatments adjacent crossed antithetic conditions. Consequently, prime of beingness measures are often included successful randomised objective trials (hereafter trials).
Multimorbidity, wherever individuals person 2 oregon much wellness conditions, is communal and important arsenic it is powerfully associated with higher mortality and hospitalisation rates [4,5], and treatments that person been shown successful objective trials to amended prime of beingness are prescribed to radical with multimorbidity little often than those without immoderate comorbidities [6,7]. Cross-sectional associations betwixt multimorbidity and prime of beingness person been reported [8–22]. Health-related prime of beingness has been identified arsenic an indispensable halfway result successful multimorbidity probe [23]. Despite this, fewer studies person examined whether multimorbidity predicts alteration successful prime of beingness implicit clip [24–29], and whether the effect of treatments connected prime of beingness disagree according to the beingness and grade of multimorbidity is unknown. Consequently, clinicians, regulatory agencies, and line developers are uncertain arsenic to the applicability of proceedings prime of beingness findings for radical with multimorbidity.
In erstwhile idiosyncratic subordinate information (IPD) analyses from a acceptable of 124 objective trials ranging crossed a fig of scale conditions and attraction comparisons, we person antecedently shown that multimorbidity, though underrepresented is contiguous among proceedings participants and predicts accrued rates of some superior adverse events and proceedings attrition [5,30,31]. Using the 56 trials from this acceptable for which measures of prime of beingness are available, we present purpose to find whether comorbidity count, which is accrued successful multimorbidity, predicts alteration successful prime life, and whether attraction effects connected prime of beingness disagree by comorbidity number astatine baseline.
Methods
This survey is reported arsenic per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) line (S1 PRISMA Checklist).
Design
We performed a meta-analysis of proceedings IPD to find the associations betwixt comorbidity number and (i) prime of beingness astatine baseline; (ii) alteration successful prime of beingness astatine proceedings follow-up; and (iii) the effect of attraction connected alteration successful prime of beingness astatine proceedings follow-up. Each investigation was done successful 2 stages to relationship for the information that proceedings information were stored securely connected abstracted platforms and could not beryllium analysed unneurotic successful a azygous model. In the archetypal stage, associations for idiosyncratic trials were modelled wrong each unafraid proceedings investigation platform. In the 2nd stage, the coefficients (and modular errors) from the archetypal signifier were meta-analysed utilizing Bayesian linear models. We utilized a method that allowed partial pooling crossed scale conditions and cause attraction comparisons successful bid to get wide cause attraction examination circumstantial and index-condition circumstantial estimates of these associations.
Trial inclusion
Industry sponsored randomised trials with disposable IPD were identified utilizing a prespecified protocol (Prospero CRD42018048202) [32]. The afloat enactment process and investigation program has been documented antecedently [30].
In brief, the United States objective proceedings registry astatine clinicaltrials.gov [33] was searched for eligible studies gathering the pursuing criteria; randomised signifier 2/3, 3 oregon 4 trials studying preselected cause classes utilized to dainty oregon forestall 23 selected semipermanent aesculapian scale conditions, registered from January 1990 until the dates of archetypal IPD entree connected 21 November 2016 and 18 May 2018, for Clinical Study Data Request (CSDR) and Yale University Open Data Access (YODA) repositories, respectively. Trials were excluded wherever they examined attraction for neoplastic, infectious, affective, psychotic, oregon developmental disorders. Trials were included if they were registered to clinicaltrials.gov [33] and had IPD availability wrong CSDR oregon YODA IPD repositories astatine the clip of the archetypal information petition to these platforms. To marque businesslike usage of expert clip (both ours and that of the proceedings sponsors who anonymised the IPD), included trials were constricted to those with ≥300 participants. Given our absorption connected comorbidity, trials were excluded if they constricted participants to those aged little than 60 years old. For the existent analysis, this acceptable of trials was restricted to those with astatine slightest 1 generic health-related prime of beingness measure. As our purpose successful the existent investigation was to analyse the interaction crossed a scope of scale conditions, we did not see trials which lone included condition-specific measures of health-related prime of beingness (e.g., St. George’s Respiratory Questionnaire). Included trials were categorised based connected scale aesculapian information and the World Health Organization Anatomic Therapeutic Chemical (ATC) cause people of the involution cause [34].
Comorbidity data
A comorbidity number was calculated for each proceedings participant. Twenty-one conditions were included successful the count: cardiovascular disease, chronic pain, arthritis, affective disorders, acid-related disorders, asthma/chronic obstructive pulmonary disease, diabetes mellitus, osteoporosis, thyroid disease, thromboembolic disease, inflammatory conditions, benign prostatic hyperplasia, gout, glaucoma, urinary incontinence, erectile dysfunction, psychotic disorders, epilepsy, migraine, parkinsonism, and dementia.
The methods utilized to deduce this number person been described antecedently [30,35]. Briefly, wherever lone information connected concomitant medicine was available, circumstantial ATC codes were utilized to specify conditions (e.g., usage inhaled of corticosteroids indicated the beingness of asthma oregon chronic obstructive pulmonary disease). Where aesculapian past information was besides available, circumstantial aesculapian dictionary for regulatory activities (MedDRA) codes were additionally utilized to place individuals with immoderate of the 21 conditions. The comorbidity counts were summed for each participant. The afloat database of ATC and MedDRA codes and the investigation codification utilized to deduce the comorbidity number are disposable astatine the project’s GitHub repository (https://github.com/ChronicDiseaseEpi/como_qol_public).
Outcome measures
Trials reported EQ-5D, SF-36, oregon both. EQ-5D is simply a preference-based generic health-related prime of beingness questionnaire with 5 domains (mobility, self-care, accustomed activities, pain/discomfort, and anxiety/depression) and a planetary measurement of existent wellness (measured via a ocular analogue scale). Given EQ-5D is penchant based, incorporating values for wellness outcomes, it tin beryllium utilized successful cost-effectiveness analyses [36]. The domains are scored connected either a 3 oregon 5 level standard (EQ-5D-3L oregon EQ-5D-5L). Since trials successful our investigation included either type, but not both, we mapped each to a azygous EQ-5D scale worth (using United Kingdom population-based worth sets for EQ-5D-3L and EQ-5D-5L, respectively, to get a azygous worth that is comparable crossed each the EQ-5D trials [37]). EQ-5D scale tin scope from antagonistic values (reflecting a authorities felt to beryllium “less preferable than death”), done 0 being “a authorities arsenic atrocious arsenic death” to 1 being “perfect health” [2].
The SF-36 questionnaire is besides a commonly utilized generic prime of beingness instrumentality and includes 36 questions implicit 8 domains. Each domain people provides a weighted summary worth of the questions wrong that domain. These domain scores are past summarised utilizing a carnal constituent people (PCS) and a intelligence constituent people (MCS). As is standard, we calculated these by archetypal standardising the scales to z scores, past aggregating the carnal and intelligence domains and transforming these into summary t scores ranging from 0 to 100 with higher scores denoting higher prime of beingness [3]. SF-36-PCS and SF-36-MCS scores are known to beryllium correlated and truthful findings for each should not interpreted arsenic if they provided autarkic verification [38].
Treatment arms
Treatment limb comparisons were specified anterior to undertaking the prime of beingness analyses. For multi-arm trials, the astir utmost arms were selected for examination (e.g., if antithetic dosages were used, the highest dose was compared to placebo oregon accustomed care—e.g., canagliflozin 300 mg, alternatively than 100 mg, versus placebo). Where placebo oregon accustomed attraction was included arsenic a attraction arm, this was selected arsenic the comparator. Otherwise, we chose the limb with the oldest attraction arsenic the comparator arm.
Statistical analysis
Summary statistic were calculated for each scale information for the disposable EQ-5D and SF-36 trials including property (mean and modular deviation; SD), enactment (number and %), and comorbidity number (mean and SD) and proportionality with 0, 1 oregon 2, oregon much comorbidities.
Full descriptions of the modelling are provided successful the supplementary (S1 Modelling description) and are described concisely below.
- (i) Association betwixt comorbidity number and prime of beingness astatine baseline
In linear regression models, for each proceedings and each measure, baseline prime of beingness was modelled adjusting for property (per 15-year increment, which was adjacent to the SD for astir trials), enactment (male versus referent radical of females), and comorbidity number (per further comorbidity). The effect measurement estimates and associated modular errors for each exemplary were past exported from the YODA and CSDR unafraid investigation platforms. In bid to person the measures onto a akin scale, we standardised each; we did truthful by dividing the estimates and modular errors by published estimates of the modular deviation (EQ-5D-index– 0.23 [39], SF-36-PCS—9.08, and SF-36-MCS– 10.16 [40]).
The effect measurement estimates for comorbidity number (adjusted for property and sex) presumption were past separately meta-analysed successful Bayesian linear regression models. We utilized Bayesian models since these allowed partial pooling crossed scale conditions and attraction comparisons and due to the fact that they allowed america to get credible intervals for estimates astatine the level of scale information and attraction examination straight from the posterior without a request for station hoc calculations. We fitted a scope of meta-analyses, from the simplest wherever each trial-level estimates were pooled (ignoring attraction examination and scale condition), done models wherever determination was partial pooling betwixt either scale conditions oregon attraction comparisons, to the astir analyzable exemplary wherever the estimates were partially pooled crossed some attraction comparisons and scale condition. The Bayesian models were fitted utilizing the brms bundle [41] successful R statistical software. Samples from the posterior organisation for each relation was summarised arsenic the mean and the 2.5th and 97.5th percentiles (credible intervals) of the posterior distribution. The proportionality of the organisation little than 0 (probability of antagonistic association, i.e., Bayesian P) was besides reported.
- (ii) Association betwixt comorbidity number and alteration successful prime of beingness astatine proceedings follow-up
We obtained estimates likewise for the relation betwixt comorbidity number and alteration successful health-related prime of beingness from baseline to proceedings follow-up by fitting the aforesaid models but with last prime of beingness people arsenic the result and a word for the baseline people successful the trial-level linear regression models.
- (iii) Association betwixt comorbidity number and the effect of attraction connected alteration successful prime of beingness astatine proceedings follow-up
Lastly, we obtained estimates for comorbidity count–treatment interactions for alteration successful health-related prime of beingness from baseline to proceedings follow-up by fitting the aforesaid exemplary arsenic (ii) with further presumption for attraction limb and an arm–comorbidity number interaction. We repeated this exemplary successful a sensitivity investigation aft excluding trials that did not show a payment successful prime of life.
In bid to let different researchers to usage the treatment–covariate enactment results to pass consequent analyses (e.g., arsenic an informative prior), we obtained samples from the posterior. We obtained samples for scale conditions and attraction comparisons included successful our model, arsenic good arsenic for a notional caller scale information and caller attraction examination not included successful our model. We summarised these samples arsenic pupil t-distributions. As with the main analysis, these models were acceptable utilizing the brms bundle (S1 Modelling description for further details).
Ethics support and consent to participate
Ethical support was obtained from the University of Glasgow, College of Medicine, Veterinary and Life Sciences morals committee (200160070).
Results
Included trials
Of the 124 trials gathering our criteria [30,32], 56 provided 1 oregon much prime of beingness measures. Twenty-five trials (19,070 participants) provided EQ-5D only, 21 trials (8,595 participants) provided SF-36 only, and 10 trials provided some measures (5,756 participants) (Fig 1). One further proceedings that had collected EQ-5D and SF-36 was excluded arsenic these results had been redacted by the survey sponsors arsenic portion of the anonymisation process [42].
Fig 1. PRISMA diagram for included trials successful prime of beingness analyses.
Flow diagram of included trials with IPD and reporting QoL measures; EQ-5D oregon the 36-item abbreviated signifier survey (SF-36). IPD, idiosyncratic subordinate data; QoL, prime of life.
The characteristics of the 56 included trials were summarised by scale information (Table 1). The clinicaltrials.gov nationalist objective proceedings (NCT) identifiers of the included trials tin beryllium recovered successful the Supporting accusation (Table A successful S1 Additional figures tables). Index conditions were axial spondyloarthritis, chronic idiopathic urticaria, dementia, benignant 2 diabetes mellitus, pulmonary hypertension, inflammatory bowel disease, migraine, osteoporosis, Parkinson’s disease, psoriasis, psoriatic arthropathy, pulmonary fibrosis, restless limb syndrome, rheumatoid arthritis, systemic lupus erythematosus (SLE), and thromboembolism. Not each arms were analysed from multi-arm trials; therefore, though included trials were constricted to those with ≥300 participants, the fig of analysed participants per proceedings ranged from 102 to 2,568 participants. Approximately 82.1% of trials had a placebo oregon accustomed attraction limb arsenic the comparator. The follow-up ranged from 6 to 104 weeks. Mean follow-up was 34.5 weeks. Thirty-seven trials and 19 trials were analysed connected the CSDR and YODA platforms, respectively. The mean property of proceedings participants ranged from 38 years successful SLE trials to 73 years successful dementia trials and the percent of antheral participants ranged from 6% successful SLE trials to 79% successful pulmonary fibrosis trials.
As we had entree to IPD, we were capable to marque the pursuing assessments of proceedings robustness to imaginable biases: 94.6% were astatine slightest treble blinded (double unsighted n = 26, triple unsighted n = 8, quadruple unsighted n = 19), determination being lone 3 unfastened statement trials. Participant completion ranged from 38.4% to 100%, with a mean (SD) completion of 81.1% (13.2%) (median 83.3% and IQR 71.4% to 90.6%). Given this is an IPD investigation determination was nary reporting bias.
Comorbidity counts
As published previously, participants with comorbidities were contiguous successful trials for each scale conditions [30]. Trials of selective immunosuppressants successful SLE had the lowest proportionality of participants with nary comorbidities (6%) and the highest proportionality of participants with ≥2 comorbidities (66%). Trials of tumour necrosis origin α (TNF-α) inhibitors successful rheumatoid arthritis had the lowest proportionality with ≥2 comorbidities (12%). Over fractional of participants successful trials with SLE, pulmonary fibrosis, osteoporosis, pulmonary hypertension, and chronic idiopathic urticaria arsenic the scale condition, had 2 oregon much comorbidities.
Comorbidity number and prime of beingness astatine baseline
The mean baseline EQ-5D scale scores and SF-36-PCS and SF-36-MCS scores varied crossed conditions and involution cause classes (Table 1). On average, participants successful trials of TNF-α drugs successful rheumatoid arthritis had the lowest mean baseline EQ-5D scale worth astatine 0.74 (0.08). The highest mean baseline EQ-5D scale worth was recovered successful participants from trials successful benignant 2 diabetes mellitus of glucagon-like peptide-1 receptor agonists and sodium glucose co-transporter 2 inhibitors 0.92 (0.09).
The lowest SF-36 constituent scores were seen successful SLE trials of selective immunosuppressants with a mean SF-36-PCS 27.9 (2.5) and SF-36-MCS 20.68 (2.09). The highest SF-36 constituent scores, SF-36-PCS 66.42 (13.37) and SF-36-MCS 63.67 (13.89), were seen successful psoriasis trials of interleukin inhibitors.
Across each scale conditions and attraction comparisons, determination was a antagonistic relation betwixt comorbidity number and prime of beingness astatine baseline, erstwhile adjusted for property and sex, for each 3 measures: EQ-5D effect estimation −0.04 standardised units (95% CI −0.05, −0.02; Bayesian P > 0.999) per further comorbidity; SF-36-PCS effect estimation −0.13 standardised units (95% CI −0.2, −0.06; Bayesian P > 0.999) per further comorbidity; SF-36-MCS effect estimation −0.1 standardised units (95% CI −0.15, −0.04; Bayesian P = 0.999) per further comorbidity.
Comorbidity number astatine baseline and consequent alteration successful prime of life
For each measures, comparative to individuals without comorbidity, determination was a alteration successful prime of beingness implicit the people of the proceedings among participants with higher comorbidity counts. Table 2 shows these associations per one-unit increment successful comorbidity count. The associations were akin successful the simplest exemplary wherever each trials were simply pooled and successful the much analyzable models wherever proceedings was nested wrong scale information and/or cause people (Table 2). For EQ-5D, nary exemplary included the null (i.e., nary association). For the SF-36 models, the results varied somewhat by model. The 95% credible interval including the null for the exemplary including cause people and scale information but did not see the null for the different models. However, adjacent for the SF-36-PCS model, which had the widest 95% CI, the probability (Bayesian P value) that comorbidity number was negatively associated with prime of beingness (i.e., determination was a smaller improvement/greater autumn successful prime of beingness successful those trials wherever prime of beingness improved/worsened, respectively) was 95.6%.
There was nary grounds of departure from linearity for the relation betwixt comorbidity number and prime of beingness for immoderate of the measures (Table B successful S1 Additional figures tables). This means that for a subordinate with a comorbidity number of 1 compared to a subordinate with a comorbidity number of 0 (or so for immoderate fixed one-unit increment successful comorbidity count), the summation successful prime of beingness during the proceedings was 0.02 standardised units little for EQ-5D (difference −0.02; 95% CI −0.03 to −0.01; Bayesian P worth > 0.999), 0.05 units little for SF-36-PCS, and 0.05 units little for SF-36-MCS (Table 2). Back transforming these values to the archetypal scales, this equates to 0.01 for the EQ-5D index, 0.48 for the SF-36-PCS, and 0.44 for the SF-36-MCS. These associations betwixt comorbidity number and alteration successful prime of beingness are astir akin successful magnitude (per 1 further comorbidity) to the attraction effects connected alteration successful prime of beingness for the 56 trials (Figure A successful S1 Additional figures tables). Therefore, the beingness of 2 oregon much comorbidities has a larger effect than attraction connected prime of life. The associations were akin for antithetic scale conditions (Fig 2) and attraction comparisons (Fig 3).
Fig 2. EQ-5D, SF-36-PCS, and SF-36-MCS: alteration successful prime of beingness and attraction enactment by condition.
The relation of comorbidity and alteration successful prime of beingness measures with attraction enactment (orange) and without (black). Standardised effect estimates with 50%, 80%, and 95% credibility intervals per proceedings scale condition. EQ-5D, EuroQol-5 dimension; MCS, intelligence constituent score; PCS, carnal constituent score; SF-36, the 36-item abbreviated signifier survey.
Fig 3. EQ-5D, SF-36-PCS and SF-36-MCS: alteration successful prime of beingness and attraction enactment by attraction comparison.
The relation of comorbidity and alteration successful prime of beingness measures with attraction enactment (orange) and without (black). Standardised effect estimates with 50%, 80%, and 95% credibility intervals per proceedings involution ATC cause attraction comparisons. ATC, anatomic therapeutic chemical; EQ-5D, EuroQol-5 dimension; MCS, intelligence constituent score; PCS; carnal constituent score; SF-36, the 36-item abbreviated signifier survey.
Comorbidity number astatine baseline and saltation successful the effect of attraction connected prime of beingness during proceedings follow-up
There was nary grounds of an enactment betwixt comorbidity number and attraction effect connected EQ-5D, SF-36-PCS, oregon SF-36-MCS. The probability that attraction was little effectual successful improving prime of beingness successful those with a greater fig of comorbidities (Bayesian P values) ranged from 0.556 to 0.749 (Table 3). The constituent estimates for these interactions were an bid of magnitude smaller than those for comorbidity number and alteration successful prime of beingness (see erstwhile section). This was existent crossed scale conditions (Fig 2) and attraction comparisons (Fig 3), and the associations were null crossed each models from the simplest wherever each trials were pooled to the astir analyzable wherever proceedings was nested wrong attraction examination and scale condition. Summarised posterior predictions (as pupil t-distributions) tin beryllium recovered successful Table C successful S1 Additional figures tables, for usage by different researchers arsenic informative priors for consequent analyses. We besides repeated the enactment investigation aft excluding the trials (23 EQ-5D, 20 SF-36-PCS, and 23 SF-36-MCS) that did not show a payment successful prime of life; the findings were likewise null (Table D successful S1 Additional figures tables).
Discussion
In an IPD meta-analysis of 56 objective trials crossed 16 scale conditions and 14 attraction comparisons, we recovered that a higher comorbidity number astatine baseline was associated with poorer prime of beingness astatine baseline (as measured by EQ-5D, SF-36-PCS, and SF-36-MCS). The higher comorbidity number astatine baseline besides predicted little betterment successful EQ-5D implicit time. The findings were similar, but with wider 95% CIs which successful immoderate models conscionable included the null, for SF-36-PCS and SF-36-MCS. However, baseline comorbidity number was not associated with differences successful the estimated effect of attraction connected prime of beingness for immoderate of these measures.
Ours is the largest study, to our knowledge, to analyse whether comorbidity predicts alteration successful prime of beingness implicit clip oregon successful effect to attraction successful proceedings participants [24–29]. However, determination are respective limitations. First though comorbidity must, by explanation summation with increases successful multimorbidity, a elemental number specified arsenic we utilized does not seizure the afloat complexity of multimorbidity, including issues specified arsenic interactions betwixt concordant and discordant conditions [43]. It is plausible that much nuanced measures of multimorbidity, feasible successful trials designed to cod multimorbidity accusation prospectively, would pb to much nuanced results arsenic to, for example, the effect of circumstantial combinations of conditions connected prime of beingness and heterogeneity of attraction effects. Moreover, portion determination was nary grounds of immoderate departure from linearity with the scope of comorbidity counts we observed, this whitethorn not beryllium existent for higher comorbidity counts. Similarly, attraction should beryllium taken erstwhile applying our findings to individuals with little prime of beingness pretreatment, since the prime of beingness scores successful the proceedings participants were mostly reasonably precocious astatine baseline. Secondly, the trials analysed were lone those disposable via the CSDR and YODA proceedings repositories. Not each sponsors stock information via these repositories, and among sponsors who do, not each trials are shared. Therefore, our dataset is not typical of each objective trials, adjacent for those scale conditions and attraction comparisons included. As trials were identified from the US objective trials registry (clinicaltrials.gov) alternatively than a database of published papers (e.g., PubMed), determination was nary hazard of work bias. However, this does not mean that the trials were a random oregon implicit illustration of each registered trials. As we person noted antecedently [44], this acceptable of trials were broadly akin to trials wherever IPD was not disposable with respect to the acceptable indications, phases, fig of participants, commencement dates, and exclusion criteria. However, inflammatory bowel illness and arthritis trials and trials of immunosuppressants were overrepresented, portion signifier 4 trials and those with particularly ample enrolment sizes were underrepresented.
Thirdly, portion our definitions were prespecified, based connected high-quality data, and person antecedently been utilized to show associations betwixt comorbidity and some proceedings withdrawal and proceedings superior adverse events [5,31], the trials were not designed to measurement comorbidity. It is imaginable that stronger associations whitethorn person been recovered if bespoke measures had been available. Thirdly, fewer of the proceedings participants had much than 2 comorbidities. As such, attraction should beryllium taken successful extrapolating our findings to individuals with 3 oregon much conditions arsenic good arsenic to radical with much terrible comorbidities who are apt to beryllium excluded from trials, since it is imaginable that these types of comorbidities bash modify attraction responses. Finally, our investigation was designed to analyse saltation successful attraction effects by comorbidity number not wide attraction effects. In our modelling, we shared accusation (partial pooling) crossed aggregate scale conditions and attraction comparisons, pooling much extensively than would person been due had our absorption been connected circumstantial attraction comparisons. Consequently, our investigation of comorbidity attraction interactions should not beryllium utilized to marque inferences astir the wide efficacy of circumstantial attraction comparisons, but alternatively astir plausible saltation successful attraction effects by comorbidity count.
A fig of erstwhile studies person examined cross-sectional associations betwixt multimorbidity (or the beingness of aggregate comorbidities and prime of life, consistently showing antagonistic associations [8–22]). Two systematic reviews with meta-analyses demonstrated a antagonistic association; 1 looked astatine studies successful immoderate mounting (mean simplification successful prime of beingness for each further comorbid information −1.55% (95% CI −2.97% to −0.13%) and −4.37% (95% CI −7.13% to −1.61%) for intelligence and carnal prime of life, respectively) [21], and 1 examined studies successful non-hospital settings (reduction successful prime of beingness 3.8% to 4.1% per further comorbid condition) [22]. Multimorbidity has besides been recovered to beryllium associated with little prime of beingness successful the USA Medical Expenditure sheet survey [19], a population-based survey of crab patients successful the Netherlands [20], a cross-sectional survey of 1,649 radical successful superior attraction successful India [8], and among 3,256 radical with spinal osteoarthritis identified from Korean nationalist wellness survey information [14].
In contrast, we recovered lone a tiny fig of studies that examined whether comorbidity oregon multimorbidity astatine baseline predicted longitudinal alteration successful prime of life. In a cohort survey of 1,211 adults successful Japan, multimorbidity astatine baseline predicted much accelerated diminution successful SF-36 implicit 12 months [27]. Similarly, among 1,582 radical undergoing full hep arthroplasty successful Denmark comorbidity astatine baseline was associated with a smaller summation successful prime of beingness (high comorbidity versus nary comorbidity EQ-5D alteration 0.09; 95% CI 0.02 to 0.16) [28]. In a survey comprising 351 individuals attending an Australian session for radical with analyzable chronic diseases, comorbidity number predicted much accelerated diminution successful SF-36 (−0.11 per comorbidity; −0.96 to 0.76) [29]. However, each 3 studies had important nonaccomplishment to follow-up. In a secondary investigation of a objective proceedings including 379 participants with aboriginal rheumatoid arthritis, prime of beingness measures were regressed connected multimorbidity (measured via the rheumatoid arthritis comorbidity index) utilizing linear mixed models. SF-36-PCS was recovered to alteration much rapidly among participants with multimorbidity but determination was nary relation for SF-36-MCS [25]. Two studies reported multimorbidity astatine baseline and reported longitudinal measures of prime of beingness successful radical with caput and cervix crab and prostate cancer, respectively, but neither presented effect estimates oregon 95% assurance intervals making it hard to justice whether this was owed to the debased illustration sizes [24,26]. To this literature, we adhd the reflection that successful 33,421 participants successful 56 trials crossed 16 scale conditions, baseline multimorbidity is associated with little prime of beingness astatine baseline and—at slightest for the EQ-5D-index—less betterment successful prime of beingness associated with proceedings participation.
While we did not undertake a ceremonial systematic review, successful a wide-ranging hunt including a fig of presumption for comorbidity, multimorbidity, and prime of beingness (Table E successful S1 Additional figures tables), we recovered lone 1 survey that reported findings connected saltation of attraction effects connected prime of beingness by comorbidity oregon multimorbidity. In a convenience illustration of 3 trials (1 asthma, 1 heartburn, and 1 gastric ulcer disease) [45], the reported associations differed crossed the included trials, measures of prime of beingness and measures of multimorbidity. To this sparse literature, we adhd findings, from a ample fig of participants, that determination was nary grounds of heterogeneity of attraction effect by multimorbidity for EQ-5D, SF-36-PCS, oregon SF-36-MCS.
The reflection that attraction effects connected prime of beingness did not disagree by multimorbidity (measured via a comorbidity count) astatine baseline has implications for the mentation of objective trials. Unless determination are beardown a priori reasons to judge that an effect of a attraction connected prime of beingness volition beryllium differential by comorbidity (e.g., a proceedings of a diabetes cause fixed by injection successful a instrumentality that mightiness beryllium much hard for radical with arthritis to usage whitethorn pb to differential efficacy successful those people), reports of heterogeneity from idiosyncratic trials and tiny meta-analyses should astir apt beryllium considered accidental findings. Similarly, treatments that impact analyzable regimes whitethorn besides differentially interaction prime of beingness according to the participant’s comorbidity count. For example, individuals with much comorbidities (and hence greater polypharmacy) whitethorn find further treatments either much oregon little burdensome than individuals with less comorbidities. Our findings connote that attraction efficacy estimates for EQ-5D, SF-36-PCS, and SF-36-MCS from objective trials are besides apt to beryllium applicable to settings with (at slightest modestly) higher levels of comorbidity, astatine slightest for the kinds of conditions and cause classes covered successful our analysis.
Based connected our models, for each outcome, we produced posterior predictions for comorbidity–treatment interactions for an unobserved cause people and scale information (i.e., 1 not included successful our models). These distributions correspond an estimation of the apt saltation successful attraction effect according to comorbidity number earlier seeing the proceedings information for immoderate fixed circumstantial attraction comparison. We had primitively intended to repetition the modelling aft log-transforming prime of beingness measures. However, since determination were nary interactions connected the linear standard (which is modular for these measures), we did not analyse the effect of changing scale. As such, these distributions tin beryllium utilized arsenic informative priors for consequent meta-analyses examining attraction effects successful radical with comorbidity, improving the reliability and precision of the resultant estimates. The anterior distributions we produced tin besides beryllium utilized to pass choices successful probabilistic wellness economical models that are utilized to use proceedings findings to “real-world” populations, specified arsenic successful Health Technology Assessments [46]. For example, if a proceedings was conducted among participants with less comorbidities than patients successful the people population, our findings tin beryllium utilized to exemplary the apt effect of specified treatments connected prime of beingness successful real-world settings. We observed a diminution successful prime of beingness successful participants with comorbidities, comparative to different participants. This uncovering provides caller grounds to suggest that the relation betwixt comorbidity and prime of beingness is causal. Most erstwhile studies reporting associations betwixt multimorbidity oregon comorbidity and prime of beingness person been cross-sectional [8–22], and the fewer longitudinal studies person been constricted by tiny sizes [24–26], constricted numbers of baseline conditions, oregon important nonaccomplishment to follow-up [27–29]. Our findings truthful fortify the grounds for causation betwixt comorbidity and baseline and consequent alteration successful prime of life.
There are a fig of imaginable mechanisms for the comparative diminution successful prime of beingness among radical with aggregate comorbidities. First, the diminution whitethorn beryllium a nonstop effect of the underlying conditions (alone oregon successful combination); symptoms specified arsenic pain, impaired sleep, constricted mobility, and impaired relation whitethorn progressively adversely interaction prime of beingness implicit time. Alternatively, the (non-treatment related) benefits of proceedings information specified arsenic improved entree to objective attraction whitethorn beryllium antithetic successful radical with and without comorbidity. Similarly, attending visits, undergoing procedures, and pursuing attraction regimens whitethorn besides enforce a greater attraction load among radical with comorbidity. This conception of proceedings information load is analogous to the attraction load (visits, cause regimens, etc.) described successful regular objective signifier [47], which is known to beryllium much challenging for radical with multimorbidity.
In these objective trials, higher comorbidity number is associated with little prime of beingness astatine baseline and predicts consequent comparative diminution successful EQ-5D (and astir apt SF-36) implicit time. However, the effect of attraction connected prime of beingness does not disagree by comorbidity number astatine baseline. Trial-derived estimates for attraction effects for prime of beingness are apt to beryllium applicable to radical with mean numbers of comorbidities.
Acknowledgments
This study, carried retired nether YODA Project # 2017–1746, utilized information obtained from the Yale University Open Data Access Project, which has an statement with JANSSEN RESEARCH & DEVELOPMENT, L.L.C. The mentation and reporting of probe utilizing this information are solely the work of the authors and does not needfully correspond the authoritative views of the Yale University Open Data Access Project oregon JANSSEN RESEARCH & DEVELOPMENT, L.L.C. This survey was besides carried retired nether ClinicalStudyDataRequest.com task fig 1732, utilized information from the ClinicalStudyDataRequest.com repository, who provided information from Boehringer-Ingelheim, GSK, Lilly, Roche, Takeda, and Sanofi. The mentation and reporting of probe utilizing these information are solely the work of the authors and does not needfully correspond the authoritative views of ClinicalStudyDataRequest.com oregon Boehringer-Ingelheim, GSK, Lilly, Roche, Takeda, oregon Sanofi.
References
- 1. Sherbourne CD, Sturm R, Wells KB. What Outcomes Matter to Patients?. J Gen Intern Med. 1999;14:357–363. pmid:10354256
- 2.
EQ-5D User Guides–EQ-5D. [cited 2021 Nov 19]. Available from: https://euroqol.org/publications/user-guides/.
- 3. Ware JEJ. SF-36 Health Survey Update. Spine. 2000;25:3130–3139. pmid:11124729
- 4. Wen Y-C, Chen L-K, Hsiao F-Y. Predicting mortality and hospitalization of older adults by the multimorbidity frailty index. PLoS ONE. 2017;12:e0187825. pmid:29145407
- 5. Hanlon P, Butterly E, Shah AS, Hannigan LJ, Wild SH, Guthrie B, et al. Assessing proceedings representativeness utilizing Serious Adverse Events: An observational investigation utilizing aggregate and individual-level information from objective trials and regular healthcare data. BMC Med. 2022. pmid:36303169
- 6. Smith DJ, Martin D, McLean G, Langan J, Guthrie B, Mercer SW. Multimorbidity successful bipolar upset and undertreatment of cardiovascular disease: a transverse sectional study. BMC Med. 2013;11:263. pmid:24359325
- 7. Wang PS, Avorn J, Brookhart MA, Mogun H, Schneeweiss S, Fischer MA, et al. Effects of noncardiovascular comorbidities connected antihypertensive usage successful aged hypertensives. Hypertens Dallas Tex. 1979;2005(46):273–279.
- 8. Pati S, Swain S, Knottnerus JA, Metsemakers JFM, van den Akker M. Health related prime of beingness successful multimorbidity: a primary-care based survey from Odisha. India Health Qual Life Outcomes. 2019;17:116. pmid:31277648
- 9. Fortin M, Dubois M-F, Hudon C, Soubhi H, Almirall J. Multimorbidity and prime of life: a person look. Health Qual Life Outcomes. 2007;5:52. pmid:17683600
- 10. Fortin M, Lapointe L, Hudon C, Vanasse A, Ntetu AL, Maltais D. Multimorbidity and prime of beingness successful superior care: a systematic review. Health Qual Life Outcomes. 2004;2:51. pmid:15380021
- 11. Brettschneider C, Leicht H, Bickel H, Dahlhaus A, Fuchs A, Gensichen J, et al. Relative Impact of Multimorbid Chronic Conditions connected Health-Related Quality of Life–Results from the MultiCare Cohort Study. PLoS ONE. 2013;8:e66742. pmid:23826124
- 12. Chen W, Lynd LD, FitzGerald JM, Marra CA, Rousseau R, Sadatsafavi M. The added effect of comorbidity connected health-related prime of beingness successful patients with asthma. Qual Life Res Int J Qual Life Asp Treat Care Rehabil. 2015;24:2507–2517. pmid:26038225
- 13. Fraser SD, Barker J, Roderick PJ, Yuen HM, Shardlow A, Morris JE, et al. Health-related prime of life, functional impairment and comorbidity successful radical with mild-to-moderate chronic kidney disease: a cross-sectional study. BMJ Open. 2020;10:e040286. pmid:32764092
- 14. Kim S-K, Choe J-Y. Comorbidities and Health-Related Quality of Life successful Subjects with Spine Osteoarthritis astatine 50 Years of Age oregon Older: Data from the Korea National Health and Nutrition Examination Survey. Medicina (Kaunas). 2022;58:126. pmid:35056434
- 15. Adams RJ, Wilson DH, Taylor AW, Daly A, Tursan d’Espaignet E, Dal Grande E, et al. Coexistent chronic conditions and asthma prime of life: a population-based study. Chest. 2006;129:285–291. pmid:16478843
- 16. Al-Asadi AM, Klein B, Meyer D. Multiple comorbidities of 21 intelligence disorders and relationships with psychosocial variables: a survey of the online appraisal and diagnostic strategy wrong a web-based population. J Med Internet Res. 2015;17:e55. pmid:25803420
- 17. Millá-Perseguer M, Guadalajara-Olmeda N, Vivas-Consuelo D, Usó-Talamantes R. Measurement of health-related prime by multimorbidity groups successful superior wellness care. Health Qual Life Outcomes. 2019;17:8. pmid:30634992
- 18. Nelis SM, Wu Y-T, Matthews FE, Martyr A, Quinn C, Rippon I, et al. The interaction of co-morbidity connected the prime of beingness of radical with dementia: findings from the IDEAL study. Age Ageing. 2019;48:361–367. pmid:30403771
- 19. Sullivan PW, Ghushchyan VH, Bayliss EA. The interaction of co-morbidity load connected preference-based health-related prime of beingness successful the United States. Pharmacoeconomics. 2012;30:431–442. pmid:22452633
- 20. Vissers PAJ, Thong MSY, Pouwer F, Zanders MMJ, Coebergh JWW, van de Poll-Franse LV. The interaction of comorbidity connected Health-Related Quality of Life among crab survivors: analyses of information from the PROFILES registry. J Cancer Surviv Res Pract. 2013;7:602–613. pmid:23918453
- 21. Makovski TT, Schmitz S, Zeegers MP, Stranges S, van den Akker M. Multimorbidity and prime of life: Systematic lit reappraisal and meta-analysis. Ageing Res Rev. 2019;53:100903. pmid:31048032
- 22. Schmitz S, Makovski TT, Adams R, van den Akker M, Stranges S, Zeegers MP. Bayesian Hierarchical Models for Meta-Analysis of Quality-of-Life Outcomes: An Application successful Multimorbidity. Pharmacoeconomics. 2020;38:85–95. pmid:31583600
- 23. Smith SM, Wallace E, Salisbury C, Sasseville M, Bayliss E, Fortin M. A Core Outcome Set for Multimorbidity Research (COSmm). Ann Fam Med. 2018;16:132–138. pmid:29531104
- 24. Daskivich TJ, van de Poll-Franse LV, Kwan L, Sadetsky N, Stein DM, Litwin MS. From atrocious to worse: comorbidity severity and prime of beingness aft attraction for early-stage prostate cancer. Prostate Cancer Prostatic Dis. 2010;13:320–327. pmid:20838413
- 25. Stouten V, Westhovens R, De Cock D, Van der Elst K, Pazmino S, Bertrand D, et al. Having a co-morbidity predicts worse result successful aboriginal rheumatoid arthritis contempt intensive treatment: a station hoc valuation of the pragmatic randomized controlled CareRA trial. Rheumatology (Oxford). 2021;60:3699–3708. pmid:33434277
- 26. Oozeer NB, Benbow J, Downs C, Kelly C, Welch A, Paleri V. The effect of comorbidity connected prime of beingness during radiotherapy successful caput and cervix cancer. Otolaryngol Head Neck Surg. 2008;139:268–272. pmid:18656727
- 27. Aoki T, Fukuhara S, Fujinuma Y, Yamamoto Y. Effect of multimorbidity patterns connected the diminution successful health-related prime of life: a nationwide prospective cohort survey successful Japan. BMJ Open. 2021;11:e047812. pmid:34127493
- 28. Glassou EN, Pedersen AB, Aalund PK, Mosegaard SB, Hansen TB. Is summation successful health-related prime of beingness aft a full hep arthroplasty depended connected the comorbidity burden? Acta Orthop. 2018;89:374–379. pmid:29621916
- 29. Tyack Z, Frakes K, Barnett A, Cornwell P, Kuys S, McPhail S. Predictors of health-related prime of beingness successful radical with a analyzable chronic illness including multimorbidity: a longitudinal cohort study. Qual Life Res. 2016;25:2579–2592. pmid:27048497
- 30. Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, et al. Representation of radical with comorbidity and multimorbidity successful objective trials of caller cause therapies: an individual-level subordinate information analysis. BMC Med. 2019;17:201. pmid:31711480
- 31. Lees JS, Hanlon P, Butterly EW, Wild SH, Mair FS, Taylor RS, et al. Effect of age, sex, and morbidity number connected proceedings attrition: meta-analysis of idiosyncratic subordinate level information from signifier 3/4 manufacture funded objective trials. BMJ Med. 2022:1.
- 32.
Prospero registration. [cited 2022 Feb 22]. Available from: https://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018048202&ID=CRD42018048202.
- 33.
Home—ClinicalTrials.gov. [cited 2020 Jul 1]. Available from: https://clinicaltrials.gov/.
- 34.
WHOCC—ATC/DDD Index. [cited 2022 Feb 22]. Available from: https://www.whocc.no/atc_ddd_index/.
- 35. Hanlon P, Jani BD, Butterly E, Nicholl B, Lewsey J, McAllister DA, et al. An investigation of frailty and multimorbidity successful 20,566 UK Biobank participants with benignant 2 diabetes. Commun Med. 2021;1:1–9. pmid:35602215
- 36. Neumann PJ, Goldie SJ, Weinstein MC. Preference-based measures successful economical valuation successful wellness care. Annu Rev Public Health. 2000;21:587–611. pmid:10884966
- 37.
Valuation of EQ-5D –EQ-5D. [cited 2022 Oct 14]. Available from: https://euroqol.org/eq-5d-instruments/valuation-of-eq-5d/.
- 38. Taft C, Karlsson J, Sullivan M. Do SF-36 Summary Component Scores Accurately Summarize Subscale Scores? Qual Life Res. 2001;10:395–404. pmid:11763202
- 39.
Kind P, Hardman G, Macran S. UK colonisation norms for EQ-5D. Centre for Health Economics, University of York; 1999 Nov. Report No.: 172chedp. Available from: https://ideas.repec.org/p/chy/respap/172chedp.html.
- 40. Garratt AM, Stavem K. Measurement properties and normative information for the Norwegian SF-36: results from a wide colonisation survey. Health Qual Life Outcomes. 2017;15:51. pmid:28292292
- 41. brms: An R Package for Bayesian Multilevel Models Using Stan. J Stat Softw. [cited 2022 Feb 22]. Available from: https://www.jstatsoft.org/article/view/v080i01.
- 42.
Anonymisation of Clinical Trial Datasets. Available from: https://clinicalstudydatarequest.com/Documents/Anonymisation%20of%20Clinical%20Trial%20Datasets.pdf.
- 43.
Overview | Multimorbidity: objective appraisal and absorption | Guidance | NICE. [cited 2022 Oct 14]. Available from: https://www.nice.org.uk/guidance/ng56.
- 44. Hanlon P, Hannigan L, Rodriguez-Perez J, Fischbacher C, Welton NJ, Dias S, et al. Representation of radical with comorbidity and multimorbidity successful objective trials of caller cause therapies: an individual-level subordinate information analysis. BMC Med. 2019;17:201– Appendix 8. Available from: https://static-content.springer.com/esm/art%3A10.1186%2Fs12916-019-1427-1/MediaObjects/12916_2019_1427_MOESM8_ESM.pdf. pmid:31711480
- 45. Xuan J, Kirchdoerfer LJ, Boyer JG, Norwood GJ. Effects of comorbidity connected health-related quality-of-life scores: an investigation of objective proceedings data. Clin Ther. 1999;21:383–403. pmid:10211540
- 46. Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence Synthesis for Decision Making 1: Introduction. Med Decis Making. 2013;33:597–606. pmid:23804506
- 47. Mair FS, May CR. Thinking astir the load of treatment. BMJ. 2014;349:g6680. pmid:25385748
English (US)